Philips IntelliSite Pathology Solution approved by the Ministry of Food and Drug Safety for diagnostic use in South Korea

Philips IntelliSite Pathology Solution

Seoul, South Korea, 13-Jul-2018 — /EuropaWire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that its Philips IntelliSite Pathology Solution has been approved by the Ministry of Food and Drug Safety (MFDS) for diagnostic use in South Korea. Pathologists can now use the digital pathology technology from Philips to assess and diagnose clinical histology cases digitally, instead of with a microscope, with the aim to enhance  laboratory efficiency and quality.

“MFDS approval for the Philips IntelliSite Pathology Solution is an important step toward innovating pathology services in South Korea,” said Marlon Thompson, General Manager of Philips Digital Pathology Solutions. “Not only will implementing digital pathology promote increased efficiencies and collaboration between pathologists within South Korea and abroad, but it also unlocks opportunity in the future for computational pathology, which aims to increase accuracies and enhance patient care.”

MFDS approval for the Philips IntelliSite Pathology Solution is an important step toward innovating pathology services in South Korea. Marlon Thompson General Manager of Philips Digital Pathology Solutions.

Pathology services are under pressure to meet the increasingly complex demands of cancer care. As the number of cancer cases continues to grow, the complexity and number of tests have simultaneously increased to support improved patient care. Pathologists must work as efficiently and effectively as possible to analyze the complex information that influences the design of personalized treatments. Outside Korea, where CE-IVD mark has allowed primary diagnosis since 2014, digital pathology is recognized for increased efficiencies in the logistical and consultative needs in primary diagnosis of histopathology images.

Philips IntelliSite Pathology Solution is an automated digital pathology image creation, viewing and management system comprised of an ultra-fast scanner and image management system. This solution contains advanced software tools to manage the scanning, storage, presentation, reviewing, and sharing of images. Philips IntelliSite Pathology Solution is available globally for primary diagnostic use. In addition to its CE-IVD clearance, it was the first – and currently only – digital pathology solution allowed to be marketed for primary diagnostic use in the U.S. since April 2017 and in Japan since December 2017.

To learn more about Philips’ innovation in digital pathology, visit Philips Digital Pathology Solutions website and follow @Philips_Path.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2017 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Media Contact

Joost Maltha
Philips Group Press Office
Tel: +31 6 10 55 8116

SOURCE: Koninklijke Philips N.V.

Comments are closed.